Evotec SE (NASDAQ:EVO – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 338,948 shares traded hands during mid-day trading, an increase of 208% from the previous session’s volume of 110,085 shares.The stock last traded at $5.31 and had previously closed at $5.25.
Analyst Ratings Changes
Several brokerages recently weighed in on EVO. HC Wainwright cut their target price on shares of Evotec from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th. Finally, Royal Bank of Canada upgraded Evotec from a “sector perform” rating to an “outperform” rating in a report on Thursday, January 18th.
Read Our Latest Analysis on EVO
Evotec Stock Performance
Institutional Investors Weigh In On Evotec
A number of large investors have recently modified their holdings of the company. Quadrant Capital Group LLC purchased a new stake in Evotec during the 4th quarter worth about $25,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after buying an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC purchased a new position in Evotec during the 4th quarter worth approximately $53,931,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
- Five stocks we like better than Evotec
- What is the NASDAQ Stock Exchange?
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Financial Services Stocks Investing
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- Comparing and Trading High PE Ratio Stocks
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
